Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Inozyme Pharma, Inc. (INZY)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 61,760,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Inozyme Pharma is a rare disease biopharmaceutical company developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Co.'s product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ectonucleotide pyrophosphatase/phosphodiesterase 1 and adenosine triphosphate-Binding Cassette in the C6 Deficiencies. This pathway is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 2,615,956 6,305,480
Total Buy Value $0 $0 $13,066,053 $26,631,213
Total People Bought 0 0 2 6
Total Buy Transactions 0 0 6 14
Total Shares Sold 0 0 0 0
Total Sell Value $0 $0 $0 $0
Total People Sold 0 0 0 0
Total Sell Transactions 0 0 0 0
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 58
  Page 1 of 3  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Subramanian Sanjay SVP, CFO   •       –      –    2023-09-29 4 A $3.57 $8,279 D/D 2,319 30,398     -
   Pivotal Bioventure Partners Fund I U.g.p., Ltd   –       •      –    2023-08-01 4 B $4.80 $3,999,998 I/I 833,333 1,571,741 0.01     -
   Hopfner Robert Lorne   –       •      –    2023-08-01 4 B $4.80 $3,999,998 I/I 833,333 1,571,741 0.01     -
   Hopfner Robert Lorne Director   –       •      –    2023-05-12 4 B $6.25 $1,429,388 I/I 228,702 3,661,518 2.1     -
   Hopfner Robert Lorne Director   –       •      –    2023-05-11 4 B $6.48 $1,420,610 I/I 219,230 3,432,816 2.1     -
   Hopfner Robert Lorne Director   –       •      –    2023-03-29 4 B $4.54 $1,563,724 I/I 344,592 3,213,586 2.1     -
   Hopfner Robert Lorne Director   –       •      –    2023-03-28 4 B $4.16 $652,335 I/I 156,766 2,868,994 2.1     -
   Hopfner Robert Lorne Director   –       •      –    2023-03-27 4 B $3.70 $188,729 I/I 51,074 2,712,228 2.1     -
   Bjarke Henric Bjorn SVP, COO   •       –      –    2022-12-15 4 B $1.39 $29,885 D/D 21,500 105,441 2.74     -
   Bjarke Henric Bjorn SVP, COO   •       –      –    2022-09-30 4 A $2.28 $7,558 D/D 3,315 83,941     -
   Bolte Axel Chief Executive Officer   •       •      –    2022-09-30 4 A $2.28 $7,558 D/D 3,315 261,890     -
   Enright Patrick G 10% Owner   –       –       •   2022-04-19 4 B $3.69 $4,999,950 I/I 1,355,000 4,174,379 1.5     -
   Bolte Axel Chief Executive Officer   •       •      –    2022-04-19 4 B $3.69 $249,998 D/D 67,750 258,575 2.81     -
   Hopfner Robert Lorne Director   –       •      –    2022-04-19 4 B $3.69 $3,948,300 I/I 1,070,000 2,661,154 2.1     -
   Subramanian Sanjay SVP, CFO   •       –      –    2022-04-19 4 B $3.69 $99,999 D/D 27,100 27,100 2.74     -
   Bjarke Henric Bjorn SVP, COO   •       –      –    2022-04-19 4 B $3.69 $99,999 D/D 27,100 80,626 2.74     -
   Pivotal Bioventure Partners Fund I U.g.p., Ltd Director   –       •      –    2022-04-19 4 B $3.69 $3,948,300 I/I 1,070,000 2,661,154 2.1     -
   Bolte Axel Chief Executive Officer   •       •      –    2021-06-24 4 S $0.00 $7 D/D (66,788) 190,825     -
   Bolte Axel Chief Executive Officer   •       •      –    2021-06-24 4 OE $0.98 $65,452 D/D 66,788 257,613     -
   Novo A/s 10% Owner   –       –       •   2021-01-28 4 S $21.00 $7,875,000 D/D (375,000) 2,194,379     -
   Sanofi-Aventis 10% Owner   –       –       •   2020-07-28 4 B $16.00 $1,300,000 I/I 81,250 520,125 1.5     -
   Sanofi-Aventis 10% Owner   –       –       •   2020-07-28 4 A $0.00 $0 I/I 438,875 438,875     -
   Novo A/s 10% Owner   –       –       •   2020-07-28 4 B $16.00 $6,000,000 D/D 375,000 2,569,379 2.45     -
   Novo A/s 10% Owner   –       –       •   2020-07-28 4 A $0.00 $0 D/D 2,194,379 2,194,379     -
   Rock Springs Capital Llc 10% Owner   –       –       •   2020-07-28 4 B $16.00 $9,600,000 I/I 600,000 1,067,884 1.5     -

  58 Records found
  1  2  3   
  Page 1 of 3
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed